GlassScriptPhysician profile
Richa Pandey
NPI 1922312834
$574.89
in general payments reported to CMS, 2019-2025
11 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2023: $19.48 · 2024: $134 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318 · Education: $49.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.89 |
| Education | $49.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $151.71 | 2019-2025 | Thiola |
| Amgen INC. | $89.98 | 2024-2025 | Tavneos |
| Alnylam Pharmaceuticals INC. | $75.42 | 2023-2025 | Givlaari, Oxlumo |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Akebia Therapeutics INC | $43.31 | 2024 | Vafseo |
| Calliditas Therapeutics US INC. | $35.35 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $27.03 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2025 | Jardiance |
| Cormedix INC. | $25.72 | 2024 | Defencath |
| Novo Nordisk INC | $20.07 | 2025 | |
| Fresenius USA Marketing, INC. | $18.69 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Pandey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.